FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157706519> ?p ?o ?g. }

• W2157706519 endingPage "1027" @default.
• W2157706519 startingPage "1021" @default.
• W2157706519 abstract "Sunitinib is an oral tyrosine kinase inhibitor of VEGF, PDGF, c-KIT, and flt-3 receptors. A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day. This study was conducted to evaluate sunitinib given as a powder formulation.Sunitinib 15 mg/m(2) was administered orally daily for 4 weeks on/2 weeks off to patients <21 years old with refractory solid tumors. Sunitinib capsules were opened, and the powder sprinkled onto applesauce or yogurt. Plasma levels of sunitinib and an active metabolite, SU12662, were measured, and pharmacokinetic parameters were estimated.12 patients, median age 13 (range 4-21) years, were treated. The most common first-cycle toxicities were leucopenia (n = 6), fatigue (n = 5), neutropenia (n = 4), and hypertension (n = 4). Three patients had dose-limiting toxicities (DLTs) in cycle 1 (dizziness/back pain, hand-foot syndrome, and intratumoral hemorrhage/hypoxia). A median peak plasma sunitinib concentration of 21 (range 6-36) ng/ml was reached at a median of 4 (range 4-8) h after the first dose. The median exposure (AUC(0-48)) was 585 (range 196-1,059) h ng/l. The median half-life was 23 (range 13-36) h. The median trough concentration measured before day 14 dosing was 32 (range 12-58) ng/ml.The pharmacokinetic profile of sunitinib appears similar between a powder formulation and published data using capsules. The powder formulation allows patients unable to swallow capsules to receive sunitinib." @default.
• W2157706519 created "2016-06-24" @default.
• W2157706519 creator A5001066329 @default.
• W2157706519 creator A5003353558 @default.
• W2157706519 creator A5011855588 @default.
• W2157706519 creator A5021851526 @default.
• W2157706519 creator A5027416118 @default.
• W2157706519 creator A5027468886 @default.
• W2157706519 creator A5038794162 @default.
• W2157706519 creator A5066484657 @default.
• W2157706519 creator A5073092034 @default.
• W2157706519 creator A5083758349 @default.
• W2157706519 date "2011-12-18" @default.
• W2157706519 modified "2023-09-23" @default.
• W2157706519 title "Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study" @default.
• W2157706519 cites W1975011523 @default.
• W2157706519 cites W1982134486 @default.
• W2157706519 cites W1995745999 @default.
• W2157706519 cites W2034322241 @default.
• W2157706519 cites W2039698853 @default.
• W2157706519 cites W2044254728 @default.
• W2157706519 cites W2047508936 @default.
• W2157706519 cites W2092773777 @default.
• W2157706519 cites W2109227311 @default.
• W2157706519 cites W2113788015 @default.
• W2157706519 cites W2139248078 @default.
• W2157706519 cites W2139511378 @default.
• W2157706519 cites W2149032069 @default.
• W2157706519 cites W2149456801 @default.
• W2157706519 cites W2157535532 @default.
• W2157706519 cites W2166788033 @default.
• W2157706519 cites W2166819037 @default.
• W2157706519 doi "https://doi.org/10.1007/s00280-011-1798-2" @default.
• W2157706519 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4008320" @default.
• W2157706519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22179104" @default.
• W2157706519 hasPublicationYear "2011" @default.
• W2157706519 type Work @default.
• W2157706519 sameAs 2157706519 @default.
• W2157706519 citedByCount "29" @default.
• W2157706519 countsByYear W21577065192012 @default.
• W2157706519 countsByYear W21577065192013 @default.
• W2157706519 countsByYear W21577065192014 @default.
• W2157706519 countsByYear W21577065192015 @default.
• W2157706519 countsByYear W21577065192016 @default.
• W2157706519 countsByYear W21577065192017 @default.
• W2157706519 countsByYear W21577065192018 @default.
• W2157706519 countsByYear W21577065192019 @default.
• W2157706519 countsByYear W21577065192020 @default.
• W2157706519 countsByYear W21577065192021 @default.
• W2157706519 countsByYear W21577065192022 @default.
• W2157706519 countsByYear W21577065192023 @default.
• W2157706519 crossrefType "journal-article" @default.
• W2157706519 hasAuthorship W2157706519A5001066329 @default.
• W2157706519 hasAuthorship W2157706519A5003353558 @default.
• W2157706519 hasAuthorship W2157706519A5011855588 @default.
• W2157706519 hasAuthorship W2157706519A5021851526 @default.
• W2157706519 hasAuthorship W2157706519A5027416118 @default.
• W2157706519 hasAuthorship W2157706519A5027468886 @default.
• W2157706519 hasAuthorship W2157706519A5038794162 @default.
• W2157706519 hasAuthorship W2157706519A5066484657 @default.
• W2157706519 hasAuthorship W2157706519A5073092034 @default.
• W2157706519 hasAuthorship W2157706519A5083758349 @default.
• W2157706519 hasBestOaLocation W21577065192 @default.
• W2157706519 hasConcept C112705442 @default.
• W2157706519 hasConcept C121332964 @default.
• W2157706519 hasConcept C121608353 @default.
• W2157706519 hasConcept C126322002 @default.
• W2157706519 hasConcept C126894567 @default.
• W2157706519 hasConcept C142424586 @default.
• W2157706519 hasConcept C197934379 @default.
• W2157706519 hasConcept C2777063308 @default.
• W2157706519 hasConcept C2777288759 @default.
• W2157706519 hasConcept C2778375690 @default.
• W2157706519 hasConcept C2778820342 @default.
• W2157706519 hasConcept C2779490328 @default.
• W2157706519 hasConcept C29730261 @default.
• W2157706519 hasConcept C71924100 @default.
• W2157706519 hasConcept C76318530 @default.
• W2157706519 hasConcept C87355193 @default.
• W2157706519 hasConcept C90924648 @default.
• W2157706519 hasConcept C98274493 @default.
• W2157706519 hasConceptScore W2157706519C112705442 @default.
• W2157706519 hasConceptScore W2157706519C121332964 @default.
• W2157706519 hasConceptScore W2157706519C121608353 @default.
• W2157706519 hasConceptScore W2157706519C126322002 @default.
• W2157706519 hasConceptScore W2157706519C126894567 @default.
• W2157706519 hasConceptScore W2157706519C142424586 @default.
• W2157706519 hasConceptScore W2157706519C197934379 @default.
• W2157706519 hasConceptScore W2157706519C2777063308 @default.
• W2157706519 hasConceptScore W2157706519C2777288759 @default.
• W2157706519 hasConceptScore W2157706519C2778375690 @default.
• W2157706519 hasConceptScore W2157706519C2778820342 @default.
• W2157706519 hasConceptScore W2157706519C2779490328 @default.
• W2157706519 hasConceptScore W2157706519C29730261 @default.
• W2157706519 hasConceptScore W2157706519C71924100 @default.
• W2157706519 hasConceptScore W2157706519C76318530 @default.
• W2157706519 hasConceptScore W2157706519C87355193 @default.
• W2157706519 hasConceptScore W2157706519C90924648 @default.

• next